What Is Caplyta, and Why Does It Matter? Caplyta (lumateperone) is a once‑daily atypical antipsychotic prescription medicine used to treat mental health conditions such as schizophrenia in adults. The ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...

The more common side effects of Caplyta (lumateperone) include sleepiness, nausea or vomiting, fatigue, decreased appetite, dry mouth, and dizziness. These side effects may be temporary and are ...

Caplyta is prescribed for adults to treat schizophrenia, depression related to bipolar I or II disorder, and as an add-on treatment with antidepressants for major depressive disorder (MDD) Caplyta ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...

CAPLYTA® ranked highest among FDA-approved adjunctive therapies across four measures of efficacy, based on indirect comparisons from placebo plus antidepressant therapy-controlled trials Among the ...

Caplyta (lumateperone) is a brand-name capsule prescribed for schizophrenia, bipolar depression, and major depressive disorder (MDD) in adults. Caplyta interacts with certain other drugs, including ...

Intra-Cellular Therapies, Inc. reported that CAPLYTA's net product sales reached $199.2 million in the fourth quarter of 2024, a significant 51% increase compared to the previous year, contributing to ...

BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ...